In 2012, 10 Big Pharma companies (AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche and Sanofi) recorded combined sales of $14.8 billion from products that have been approved as new molecular entities (NMEs) by the FDA since 2007. This figure equates to just 4.9 percent of total branded revenues recorded by these same 10 players in 2012.

See on www.firstwordpharma.com